Pharmacelera

Day 2 for Pharmacelera at a packed Mobile World Congress 2025! 🚀 We’re in the HealthTech and TechBio area of the 4 Years From Now (4YFN) space, and it's exciting to see big pharma actively engaging in the conversation. Just as the automotive industry realized that a car is essentially a network of interconnected chips with wheels and an engine, the pharmaceutical industry is increasingly embracing AI, quantum computing, blockchain, and other deep-tech innovations to transform drug discovery. Exciting times ahead for the future of biotech and digital health! 🔬💡 #MWC2025 #HealthTech #TechBio #AI #QuantumComputing #DeepTech #PharmaInnovation

🚀 Exciting news! Our CEO, Enric Gibert, will be attending Mobile World Congress 2025 in Barcelona from March 3rd-6th! What started as a mobile-focused event has grown into a global stage for cloud computing, IoT, AI, quantum computing, digital health, and biotech—driving innovation across industries. With 100,000+ attendees from 205 countries, MWC is the place to connect, collaborate, and explore the future of technology. Let’s meet there! Feel free to reach out to schedule a chat. 🤝 #MWC2025 #Innovation #Tech #AI #DigitalHealth #Biotech #drugdiscovery #exascreen #pharmscreen #pharmqsar #computationalchemistry #medicinalchemistry

📢 New Pharmacelera software release! We’re excited to announce Pharmacelera’s 2025.01 software update. In this version you will find the following new features: ⏩ Custom Ultra-Large Library Generation – The new exaScreen®-intra add-on allows you to generate exaScreen®-compatible libraries from your own internal Building Blocks and chemical reactions. ⏩ Advanced Filtering Options – PharmScreen® now supports enhanced substructure pattern matching, enabling more precise compound searches. ⏩ Boosted Performance & Scalability – Both PharmScreen® and exaScreen® now support processors with hundreds of threads, delivering significantly faster results. ⏩ Updated Screening Libraries – we have updated the Enamine Screening Collection and Molport libraries for PharmScreen® and the Enamine REAL Space for exaScreen®. exaScreen® is now able to mine 70 billion synthesizable compounds in 3D with our accurate QM-derived descriptors in a few hours. ⏩ Expanded File Format Support – Molecular field projections and QSAR model coefficients can now be exported in DX and GRD formats, ensuring compatibility with a wider range of visualizers. ⏩ PharmQSAR® Integration in MolXplore – You can now visualize PharmQSAR® models directly in MolXplore, making SAR analysis of QSAR coefficients more intuitive. 🙋Want to learn more? Request your trial now and get easy access to our QM-based 3D descriptors for virtual screening, scaffold hopping, machine learning and 3D QSAR modeling. https://lnkd.in/dU8PkBps #drugdiscovery #exascreen #pharmscreen #pharmqsar #computationalchemistry #medicinalchemistry #artificialintelligence #ai

The Computational Biology & Drug Design group at the Universitat de Barcelona, led by our CSO, Javier Luque, has explored druggable sites in influenza A hemagglutinin for a series of pinanamine-based antivirals. The results pave the way to exploration of the antiviral activity of novel compounds. The proposed binding mode offers valuable insights into the structure-activity relationships (SAR), enhancing the community's understanding of these interactions. At Pharmacelera, we are pleased to see that PharmScreen played a key role in rationalizing the only identified outlier, which was hypothesized to interact with the M2 proton channel. We remain committed to continuously evolving our technology to support and accelerate research in antiviral drug discovery. #DrugDiscovery 🏥 #AntiviralResearch 🦠 #ComputationalChemistry 🖥️ #MachineLearning 💡 #StructureActivityRelationships #Pharmacelera #PharmaTech 🚀

Nous avons le plaisir de vous informer que Pharmacelera  vient de recevoir son agrément Crédit d’Impôt Recherche  (Dépenses de recherche ) pour les années 2025 et 2026. Nous pouvons donc vous accompagner dès lors dans votre projet de R&D tout en vous faisant bénéficier d’une réduction d’impôt. Cette mesure d’allègement fiscal pour les entreprises axées sur des activités de Recherche & Développement pour les organismes basés en France est conçue pour toutes les entreprises soumises à l’impôt sur les sociétés ou sur le revenu, quelle que soit leur taille ou leur secteur. L’incitation est applicable aux études ou projets de Recherche & Développement sous-traités à des tiers agréés, tels que Pharmacelera. Les dépenses éligibles sont par exemple les dépenses de R&D externalisées (par des organismes agréés), les frais de personnel technique, les dépenses de fonctionnement, les frais d’amortissement, le dépôt de brevet. Vous pouvez nous contacter à l’adresse mail suivante : contact@pharmacelera.com #CréditImpôtRecherche #CIR #RechercheEtDéveloppement #Innovation #R&D #chimiemédicinale #Fiscalité #EntreprisesInnovantes #AvantageFiscal #Startups #Technologie #IndustriePharmaceutique #RechercheScientifique #DéveloppementTechnologique #Pharmacelera #ExternalisationR&D #InvestirDansLaRecherche #AideAuxEntreprises #DéductionFiscale #ProjetsInnovants #RechercheCollaborative #Ingénierie #FranceInnovation

🔎 Find the Man Impersonating Little Red Riding Hood! 🔴🧺 Are you attending the JP Morgan Healthcare Conference? Interested in the application of #ai for #drugdiscovery? You still have a chance to meet our CEO, Enric Gibert! He’s hard to miss, look for the man boldly impersonating Little Red Riding Hood! 😉🔴 Don’t miss out on connecting! #JPM2025 #HealthcareInnovation #Networking #Leadership #BreakingStereotypes #MeetTheCEO #artificialintelligence #machinelearning

  🎉✨ We just did it! – 10 Years of Excellence & Innovation 🧪💡 For one incredible decade, we’ve been honored to deliver innovative drug discovery services and provide cutting-edge technology to drive science forward. 🌟 🙏 A genuine thank you to our clients, partners, and team members who’ve been part of this remarkable journey. Your trust, collaboration, and support have shaped our history and inspired us to aim higher every day. 🚀 Here’s to another 10 years of disruptive science and transformative solutions! #Pharmacelera #Annyversary #10YearsOfExcellence #PharmaInnovation #DrugDiscovery #DisruptiveScience #CelebratingSuccess #LifeChangingScience #ThankYou 

🚀✨ We’re kicking off the year by participating in the 43rd Annual J.P. Morgan Healthcare Conference. 📊💼 Our CEO, Enric Gibert,  will join top healthcare and pharma leaders. He is ready to connect with investors, partners, and media to share our latest progress and milestones. 🌟🔬 Stay tuned for updates, and let’s make 2025 a year of innovation and growth! 🌍🤝 #Pharmacelera #JPM2025 #HealthcareInnovation #PharmaLeaders #Biotech #InvestingInTheFuture #Networking #InnovationJourney

🎄 Wishing you a joyful and relaxing holiday season! 🎄 #happyholidays #happynewyear #Pharmacelera

Using 3D Methods for Virtual Screening?? Here are key insights from our findings on query molecule conformations: • Carefully consider the query molecule conformation: Its selection plays a critical role in the identification of novel compounds, especially when aiming for greater chemical diversity. A 2D bias in the benchmarking set can undermine the impact of 3D conformations on virtual screening (VS) performance. • Address chemical diversity in internal validations: If your goal is to recover active compounds with high chemical diversity compared to the query molecule, ensure your metrics account for this challenge. • Leverage energy-minimized conformations: When targeting compounds with similar scaffolds, choosing the energy-minimized conformation of the query molecule can be beneficial, as it aligns the conformational space between the query and screened compounds due to shared chemical features. Compound libraries normally include minimized structures in a gas phase or solvent without target information. • Use X-ray conformations for specific cases: Consider X-ray conformations when the query molecule’s conformation is shaped by the binding pocket’s topology or specific interactions, as these may better reflect the bioactive state. Learn more about our study at: https://lnkd.in/deHzprHi or feel free to reach out to authors Javier Vázquez Lozano or Enric Herrero. . What’s your experience with query conformations in 3D virtual screening? Let’s discuss it! #VirtualScreening #3DMethods #DrugDiscovery #MolecularModeling #PharmaceuticalResearch #ChemistryInnovation #ComputationalChemistry #ScientificResearch #QueryOptimization